Doripenem Dosing Recommendations for Critically Ill Patients Receiving Continuous Renal Replacement Therapy

Table 1

Results of nonparametric superposition and noncompartmental analysis performed on mean data for doripenem and doripenem-M-1.

	Continuous venovenous hemofiltration				Continuous venovenous hemodiafiltration					Healthy subjects^a
	Day 1^a	Simulated steady-state (day 10)			Day 1^a	Simulated steady-state (day 10)
	500 mg; q12h	500 mg; q8h	250 mg; q8h	250 mg; q12h	500 mg; q12h	500 mg; q8h	375 mg; q12h	250 mg; q8h	250 mg; q12h	1000 mg; q8h
Doripenem
𝐶max,ss (mg/L)	24.1	29.6	14.9	13.2	22.5	26.5	17.9	13.2	12.0	44.0
AUC𝜏 (mg⋅h/L)	97.6	114	57.1	57.1	88.4	86.5	64.9	43.3	43.3	69.6
AUC24,ss (mg⋅h/L)	N/A	342.0	171.3	114.2	N/A	259.5	129.8	129.9	86.6	208.8
Doripenem-M-1
𝐶max,ss (mg/L)	3.02	8.86	4.44	3.27	3.66	9.15	5.23	4.57	3.49	9.81
AUC𝜏 (mg⋅h/L)	24.4	58.6	29.3	29.3	21.8	54.2	40.7	27.1	27.1	21.3
AUC24,ss (mg⋅h/L)	N/A	175.8	87.9	58.6	N/A	162.6	81.4	81.3	54.2	63.9

AUC_24,ss: total daily area under the curve at steady state; AUC_𝜏: area under the curve at steady state during the dosing interval 𝜏; 𝐶_max,ss: maximum plasma concentration at steady state; q8h: every 8 hours; q12h: every 12 hours.
aThe day 1 500 mg q12h CRRT data and the healthy subject data are observed results from single- and multiple dose studies. All doripenem dosing regimens were a 1-hour infusion duration.